Latest news for Universal Ibogaine (OTC:IBOGF) Stock

Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.

cristian-escobar-abkEAOjnY0s-unsplash

Biotech

Cannabis

Psychedelics

Financing

Legal

Management

Global

BWVI

CMPS

IBOGF

Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds &amp; More

UNIVERSAL IBOGAINE INC by Universal Ibogaine Inc.

Universal Ibogaine Inc

Ahead of the 2024 US presidential election, the Justice Department has unveiled charges against three Iranian hackers <a href="https://www.benzinga.com/news/24/09/40933501/us-intel-agencies-reveal-iran-tried-to-share-hacked-trump-campaign-data-with-team-biden-fbi-says-no">accused of disrupting</a> Donald Trump&#8217;s campaign.
What Happened: The U.S. Justice Department unsealed charges against three Iranian hackers for disrupting Donald Trump&#8217;s presidential campaign, Reuters reported on Friday.
The accused are members of Iran&#8217;s Revolutionary Guards Corps. They allegedly targeted the Nov. 5 election between former President Trump and Vice President Kamala Harris.
Iran dismissed the accusations as baseless. The Justice Department has also targeted Russian election interference, charging and sanctioning state media employees for funding pro-Trump influencers.
See Also: <a href="https://www.benzinga.com/news/24/09/41019829/mark-cuban-fires-back-at-criticism-of-kamala-harris-tax-policies-trump-has-a-new-tax-cut-or-tariff-f?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Fires Back At Criticism Of Kamala Harris Tax Policies</a>
Attorney General Merrick Garland stated that the hackers — Masoud Jalili, Seyyed Ali Aghamiri, and Yasar Balaghi — aimed to undermine Trump&#8217;s campaign. &#8220;We are seeing increasingly aggressive Iranian cyber activity during this election cycle,&#8221; Garland said.
The indictment alleges the hackers used fake email accounts to deceive campaign officials, stealing emails and internal documents, which were then leaked to the media and Joe Biden&#8216;s campaign. Charges include wire fraud, identity theft, and computer fraud.
The U.S. Treasury Department also imposed sanctions on the three men and other Revolutionary Guard members. The hackers are currently in Iran, out of U.S. law enforcement&#8217;s reach. Garland emphasized the Justice Department&#8217;s commitment to pursuing these individuals indefinitely.
Why It Matters: The charges against the Iranian hackers come amid heightened concerns over foreign interference in U.S. elections.
In August, <a href="https://www.benzinga.com/news/24/08/40303972/trump-campaign-falls-victim-to-cyber-attack-heightening-election-security-fears">Trump&#8217;s campaign</a> confirmed a security breach, believed to be orchestrated by foreign entities hostile to the U.S. This breach included the theft of internal documents, which were later leaked to the media.
Furthermore, Meta Platforms Inc. also <a href="https://www.benzinga.com/news/24/08/40541547/heres-how-meta-thwarted-iranian-hackers-attempt-to-target-trump-and-biden">thwarted an attempt</a> by Iranian hackers to target both Trump and Biden&#8217;s campaigns via WhatsApp accounts linked to the hacking group APT42. This group has been identified by tech giants like Google as an &#8220;Iranian state-sponsored cyber espionage actor.&#8221;
In addition, U.S. intelligence agencies revealed that Iran tried to share hacked Trump campaign data with Biden&#8217;s team. According to a <a href="https://www.benzinga.com/news/24/09/40933501/us-intel-agencies-reveal-iran-tried-to-share-hacked-trump-campaign-data-with-team-biden-fbi-says-no">joint statement</a> by the FBI, ODNI, and CISA, Iranian cyber actors sent unsolicited emails containing stolen Trump campaign material to individuals associated with Biden&#8217;s campaign.
Moreover, <a href="https://www.benzinga.com/news/24/08/40428036/openai-blocks-iranian-groups-chatgpt-accounts-for-targeting-us-election-says-covert-operation-did-no">OpenAI</a> uncovered and dismantled a covert Iranian influence operation using ChatGPT to manipulate public opinion during the 2024 elections. The operation, named Storm-2035, produced content on U.S. politics and the presidential election, shared via social media and websites posing as news outlets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41040076/trump-accuses-zelenskyy-of-making-nasty-little-dispersions-after-canceled-meeting-we-continue-to-giv?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Accuses Zelenskyy Of Making &#8216;Nasty Little Dispersions&#8217; After Canceled Meeting</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

News

Politics

Tech

US Charges Iranian Hackers For Interfering In 2024 Presidential Election

Independent American journalist Ken Klippenstein has been indefinitely barred from using Elon Musk&#8217;s social media platform X, formerly Twitter.
What Happened: This action was taken after Klippenstein on Thursday published leaked documents allegedly associated with Sen.&nbsp;JD Vance&nbsp;(R-Ohio.), the <a href="https://www.benzinga.com/news/24/09/40993779/jd-vance-is-too-radical-and-needs-to-read-up-on-the-history-of-the-second-world-war-says-ukraines-pr">running mate of Republican candidate</a> Donald Trump.
In his newsletter, Klippenstein disclosed&nbsp;a 271-page opposition research file&nbsp;on Vance, which is suspected&nbsp;to be part of an <a href="https://www.benzinga.com/news/24/09/40933501/us-intel-agencies-reveal-iran-tried-to-share-hacked-trump-campaign-data-with-team-biden-fbi-says-no">Iranian scheme to influence</a> the U.S. election.
Following the publication of these files, Klippenstein was banned from X, where he had posted a link to his report and the dossier. Now, the independent journalist has asserted that his ban from X is permanent.
&#8220;Elon Musk is an outspoken supporter of Donald Trump and J.D. Vance's political campaign,&#8221; he said. 
Adding, &#8220;X clearly doesn't want to give the appearance that my ban was politically motivated. But a careful look at the pretext X cites for my suspension makes it obvious that this is political.&#8221;
See Also: <a href="https://www.benzinga.com/news/24/09/41061660/ex-microsoft-ceo-and-billionaire-steve-ballmer-says-he-gets-most-important-stuff-from-elon-musks-x-i?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Ex-Microsoft CEO And Billionaire Steve Ballmer Says He Gets &#8216;Most Important Stuff&#8217; From Elon Musk&#8217;s X</a>
Klippenstein also said that his article discloses less private information than&nbsp;the Hunter Biden laptop story, which Musk had previously criticized Twitter for blocking.
He also points out that any user who posts a link to his article on X gets their account locked, mirroring Twitter&#8217;s handling of&nbsp;the Hunter Biden laptop story.
The journalist went on to add that X usually offers users the chance to remove posts violating its policies to reinstate their accounts.
However, he claims he received no such offer. As a test, he and his editor redacted all &#8220;private&#8221; information from the Vance Dossier on Substack and filed an appeal, yet his ban remains.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: In December 2022, after Musk acquired Twitter for $44 billion, several high-profile journalists&#8217; accounts were suspended over the <a href="https://www.benzinga.com/news/22/12/30103562/what-gives-elon-musk-twitter-nukes-accounts-of-high-profile-journalists-over-new-doxxing-policy">platform&#8217;s new &#8220;doxxing&#8221; policy</a>.
Musk has repeatedly said that his acquisition of the social media site was primarily motivated by his <a href="https://www.benzinga.com/news/24/09/40785575/elon-musk-says-x-intends-to-obey-the-law-in-each-jurisdiction-but-if-free-speech-is-not-illegal-then">commitment to&nbsp;free speech</a>. However, the recent ban on Klippenstein raises questions about the platform&#8217;s commitment to these principles.
The tech mogul has previously also <a href="https://www.benzinga.com/news/22/11/29864554/musk-says-twitter-ban-on-trump-was-grave-mistake-reveals-preferred-2024-presidential-candidate">criticized Twitter&nbsp;for banning</a> Trump and reinstated the former President&#8217;s account on X.
Meanwhile, Musk&#8217;s involvement with the Hunter Biden story was <a href="https://www.benzinga.com/news/22/11/29850290/elon-musk-says-making-internal-twitter-conversations-on-hunter-biden-laptop-story-public-necessary-t">marked by his release</a> of internal Twitter communications that detail how the platform handled a controversial article from the&nbsp;New York Post&nbsp;in October 2020.
This article alleged corruption involving Hunter Biden, particularly focusing on emails from a laptop purportedly belonging to him.
At the time, Musk said that <a href="https://www.benzinga.com/news/22/11/29850290/elon-musk-says-making-internal-twitter-conversations-on-hunter-biden-laptop-story-public-necessary-t">revealing these documents</a> was &#8220;necessary to restore public trust.&#8221;
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40974511/iphone-15-pro-models-and-iphone-13-discontinued-by-apple-heres-why?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">iPhone 15 Pro Models and iPhone 13 Discontinued By Apple: Here&#8217;s Why</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photos courtesy: Shutterstock

Social Media

Elon Musk Gets Labelled As An 'Outspoken' Trump Supporter After Journalist Gets Banned On X For Publishing Leaked JD Vance Docs: 'This Is Political'

Israel has reportedly carried out a <a href="https://www.benzinga.com/news/global/24/09/40909027/casualties-rise-from-exploding-hezbollah-pagers-us-says-it-had-no-advance-notice-of-coordinated-atta">large-scale airstrike</a> on the southern suburbs of Beirut, aiming at the leader of Hezbollah, Hassan Nasrallah.
What Happened: The airstrike, which occurred on Friday, was directed at Nasrallah, who has been at the helm of Hezbollah for over three decades, <a href="https://www.wsj.com/world/middle-east/israel-says-it-shot-down-missile-fired-from-yemen-b67c7dc5?mod=hp_lead_pos1">reported</a> The Wall Street Journal, citing people briefed on the attack.
The assault led to the destruction of several buildings, thought to be the main headquarters of Hezbollah. Nasrallah&#8217;s fate is still uncertain.
Ali al-Harakah, a local municipal official, reported numerous explosions in the Haret Hreik neighborhood, causing significant damage and possible casualties.
High-ranking officials from Hezbollah and Iran&#8217;s&nbsp;Islamic Revolutionary Guard Corps were&nbsp;allegedly at the site during the attack.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/09/41061814/british-pm-dines-with-trump-skips-meeting-with-kamala-harris-due-to-usual-diary-challenges?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">British PM Dines With Trump, Skips Meeting With Kamala Harris Due To &#8216;Usual Diary Challenges&#8217;</a>
After the initial attack, Israel&#8217;s military issued warnings to residents in certain Beirut neighborhoods, advising them to evacuate ahead of planned operations against three buildings with strategic underground capabilities, the report noted.
Additional strikes were carried out in the southern suburbs of Beirut later that night.
This aggressive action is part of Israel&#8217;s ongoing efforts to prevent Hezbollah from launching attacks&nbsp;across the Lebanese border into&nbsp;Israel.
If Nasrallah&#8217;s death is confirmed, it would deal a significant blow to Hezbollah and Iran.
Why It Matters: The strike occurred shortly after Israeli Prime Minister Benjamin Netanyahu <a href="https://www.benzinga.com/news/24/09/41071612/netanyahu-defends-israels-actions-at-un-as-tensions-with-hezbollah-escalate">delivered his speech</a> at the United Nations General Assembly in New York.
He defended Israel's actions in Gaza and Lebanon at the assembly, dismissing <a href="https://www.benzinga.com/news/24/09/40977597/us-warns-israel-against-opening-a-full-blown-war-against-hezbollah-as-air-strikes-kill-30-in-lebanon">international demands for a ceasefire</a>. &#8220;We will not accept a terror army perched on our northern border able to perpetrate another Oct. 7-style massacre,&#8221; he said.
On Thursday, Palestinian President Mahmoud Abbas told world leaders at the UN General Assembly that Israeli strikes have led to water shortages, the spread of disease, and dwindling supplies of basic medicines.
It has also been reported that Israel intends to <a href="https://www.benzinga.com/general/politics/24/09/41056542/israel-plans-to-disrupt-arms-delivery-from-iran-to-lebanon-in-motion-as-palestinian-president-cr">disrupt arms transfers</a> from Iran to Hezbollah.
Meanwhile, earlier this month, <a href="https://www.benzinga.com/news/24/09/40920151/china-slams-us-for-shielding-israel-blocking-gaza-ceasefire-efforts-as-war-nears-1-year">China accused&nbsp;the U.S.</a> of shielding Israel and obstructing ceasefire efforts.
China&#8217;s accusation comes against the backdrop of rising geopolitical tensions. In April, <a href="https://www.benzinga.com/news/24/04/38267600/amid-iran-israel-tensions-china-affirms-support-for-tehran-strengthens-ties">China reinforced its support</a> for Tehran, deepening its ties with Iran after the latter&#8217;s direct attack on Israel.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41037884/its-trump-not-harris-says-fox-anchor-bret-baier-on-delayed-second-debate?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">It&#8217;s Trump, Not Harris, Says Fox Anchor Bret Baier On Delayed Second Debate</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Following Netanyahu's UN Address, Israel Reportedly Launches Massive Airstrike Targeting Hezbollah Leader Hassan Nasrallah In Beirut

LXEH

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

CNET

SONN

High Tide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>), a retail-driven cannabis company, announced Friday that it placed No. 87 out of 417 companies listed on the 2024 Report on Business ranking of Canada's Top Growing Companies. 
High Tide achieved an impressive three-year revenue growth rate of 486%. This consistent growth earned the company a place in the index for the 4th year in a row.
<h3 class="wp-block-heading">Consistent Growth In A Competitive Market</h3>
High Tide&#8217;s ranking in 2024 follows its 2023 achievement, where it placed 38th with a remarkable growth rate of 1,040%. 
This consistent upward trajectory can be attributed to the company&#8217;s<a href="https://www.benzinga.com/markets/cannabis/24/08/40245394/high-tides-cabana-club-loyalty-program-surpasses-1-5m-members-in-canada"> strong retail strategy</a> and operational success. CEO Raj Grover highlighted the success. &#8220;Our aggressive top-line growth is being translated into free cash flow generation.&#8221;
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
This growth allowed High Tide to expand its retail presence, capturing 12% of the market share in five Canadian provinces.
High Tide's annualized run rate now exceeds $525 million, with net income reaching $0.8 million in <a href="https://www.benzinga.com/markets/cannabis/24/09/40887415/cannabis-retailer-high-tide-reports-q3-results">the last quarter</a>. 
In addition to dominating the <a href="https://www.benzinga.com/markets/cannabis/24/08/40558227/cannabis-sales-in-canada-decline-sharply-whats-behind-the-drop">Canadian market</a>, High Tide is looking to expand internationally. The company has set its sights on emerging cannabis markets in <a href="https://www.benzinga.com/markets/cannabis/24/08/40520655/25-german-cities-join-cannabis-pilot-trials-in-2024-under-new-legalization-law">Germany</a> and the United States.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40820402/canadas-largest-cannabis-retailer-high-tide-partners-to-bring-marijuana-offerings-to-events">Canada&#8217;s Largest Cannabis Retailer High Tide Partners To Bring Marijuana Offerings To Events</a>
<h3 class="wp-block-heading">About The Ranking</h3>
The full list of the 2024 winners of Canada's Top Growing Companies is featured in the October issue of Report on Business magazine, along with detailed editorial coverage.
This ranking recognizes the achievements of 417 businesses that qualified by completing a thorough application process and meeting specific revenue requirements. 
Launched in 2019, the program celebrates Canada's most forward-thinking and fast-growing companies across various sectors.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40838052/cannabis-retail-giant-high-tide-ramps-up-offering-for-millions-of-customers">Cannabis Retail Giant High Tide Ramps Up Offering For Millions Of Customers</a></li>
</ul>
Cover Image: Courtesy of High Tide Inc.

Retail Sales

Economics

Markets

HITI

High Tide Cannabis Co. Ranks Among Top Growing Businesses In Canada In 2024

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has outperformed the market over the past 15 years by 3.4% on an annualized basis producing an average annual return of 15.43%. Currently, Humana has a market capitalization of $38.48 billion. 
Buying $1000 In HUM: If an investor had bought $1000 of HUM stock 15 years ago, it would be worth $8,712.38 today based on a price of $319.57 for HUM at the time of writing.
<h3>Humana's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727472623_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 15 Years Ago Would Be Worth $8,700 Today

Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) has outperformed the market over the past 10 years by 3.22% on an annualized basis producing an average annual return of 14.6%. Currently, Ameriprise Finl has a market capitalization of $46.11 billion. 
Buying $1000 In AMP: If an investor had bought $1000 of AMP stock 10 years ago, it would be worth $3,916.59 today based on a price of $468.62 for AMP at the time of writing.
<h3>Ameriprise Finl's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727472618_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Ameriprise Finl 10 Years Ago Would Be Worth This Much Today

Across the recent three months, 12 analysts have shared their insights on Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $746.92, with a high estimate of $795.00 and a low estimate of $600.00. This current average has increased by 2.51% from the previous average price target of $728.64. 
<img src="https://www.benzinga.com/files/images/story/2024/1727470860_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Intuit among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$768.00</td>
<td>$768.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$740.00</td>
<td>$745.00</td>
</tr>
<tr>
<td>Sterling Auty</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$600.00</td>
<td>$585.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$790.00</td>
<td>$770.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$795.00</td>
<td>$690.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$760.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$780.00</td>
<td>$730.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$768.00</td>
<td>$760.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$757.00</td>
<td>$757.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$685.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$760.00</td>
<td>$760.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$760.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Intuit. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intuit compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Intuit's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INTU/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Intuit analyst ratings.</a>
<h2>About Intuit</h2>
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of US market share for small-business accounting and do-it-yourself tax-filing software.
<h3>Understanding the Numbers: Intuit's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Intuit's revenue growth over a period of 3 months has been noteworthy. As of 31 July, 2024, the company achieved a revenue growth rate of approximately 17.4%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Intuit's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -0.63%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Intuit's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.11%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Intuit's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.06%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.36, Intuit adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

INTU

Deep Dive Into Intuit Stock: Analyst Perspectives (12 Ratings)

10 analysts have expressed a variety of opinions on Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Impinj, revealing an average target of $200.0, a high estimate of $225.00, and a low estimate of $175.00. This upward trend is evident, with the current average reflecting a 15.61% increase from the previous average price target of $173.00.
<img src="https://www.benzinga.com/files/images/story/2024/1727470834_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Impinj. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Scott Searle</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$205.00</td>
<td>-</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$215.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Impinj. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Impinj compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Impinj's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Impinj's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Impinj analyst ratings.</a>
<h2>Discovering Impinj: A Closer Look</h2>
Impinj Inc operates a platform that enables wireless connectivity to everyday items by delivering each item's identity, location, and authenticity to business and consumer applications. Its platform includes endpoint integrated circuits (ICs) product, a miniature radios-on-a-chip, which attach to and identify their host items; and connectivity layer that comprises readers, gateways, and reader ICs to wirelessly identify, locate, authenticate, and engage endpoints via RAIN, as well as provide power to and communicate bidirectionally with endpoint ICs. Geographically, the company has a business presence in the Americas, Asia Pacific, Europe, Middle East and Africa, of which key revenue is derived from the operations in the Asia Pacific region.
<h3>Understanding the Numbers: Impinj's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Impinj's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 19.2%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.72%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Impinj's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.82% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Impinj's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.32% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Impinj's debt-to-equity ratio stands notably higher than the industry average, reaching 2.51. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Impinj: Insights From 10 Financial Analysts

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 10 years by 12.36% on an annualized basis producing an average annual return of 23.75%. Currently, IDEXX Laboratories has a market capitalization of $42.12 billion. 
Buying $100 In IDXX: If an investor had bought $100 of IDXX stock 10 years ago, it would be worth $846.20 today based on a price of $511.78 for IDXX at the time of writing.
<h3>IDEXX Laboratories's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727470822_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IDXX

Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 10 Years

Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) has outperformed the market over the past 15 years by 5.92% on an annualized basis producing an average annual return of 17.95%. Currently, Eaton Corp has a market capitalization of $130.76 billion. 
Buying $100 In ETN: If an investor had bought $100 of ETN stock 15 years ago, it would be worth $1,215.13 today based on a price of $328.45 for ETN at the time of writing.
<h3>Eaton Corp's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727470817_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today

AbbVie's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) short percent of float has fallen 8.18% since its last report. The company recently reported that it has 17.79 million shares sold short, which is 1.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AbbVie Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727469922_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AbbVie has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AbbVie's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AbbVie's peer group average for short interest as a percentage of float is 5.98%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

ABBV

(ABBV) - Analyzing AbbVie's Short Interest

Domino's Pizza's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) short percent of float has risen 18.23% since its last report. The company recently reported that it has 2.19 million shares sold short, which is 7.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Domino's Pizza Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727469917_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Domino's Pizza has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Domino's Pizza's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Domino's Pizza's peer group average for short interest as a percentage of float is 10.91%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Domino's Pizza's Recent Short Interest

Keurig Dr Pepper's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NYSE">KDP</a>) short percent of float has fallen 5.53% since its last report. The company recently reported that it has 21.72 million shares sold short, which is 2.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.68 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Keurig Dr Pepper Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727469911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Keurig Dr Pepper has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Keurig Dr Pepper's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Keurig Dr Pepper's peer group average for short interest as a percentage of float is 7.16%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Keurig Dr Pepper's Recent Short Interest

Deere &amp; Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/de#NYSE">DE</a>) has recalled about 147,900 compact utility tractors in the United States due to a potential brake failure risk, per reports. This voluntary recall will ensure customer safety.
The recall applies to models 1023E, 1025R and 2025R sold between November 2017 and July 2024. In Canada, the company has recalled another 16,800 of the compact utility tractor models.
The front bell crank in the brake linkage of the recalled tractors may break, endangering users in the event of a crash, according to the Consumer Product Safety Commission (&quot;CPSC&quot;). There have been four reports of brake linkage failure in the United States so far, with one hospitalization, two impact injuries and minor damages to the tractors.
<h2>Deere&#39;s Commitment to Safety</h2>
The company is proactively addressing the issue in collaboration with the U.S. CPSC.
Deere instructed the impacted customers not to operate their tractors until they receive a free repair from an authorized Deere dealer. Customers have easy access to repair services due to over 2,000 dealerships in the United States and Canada. If the consumer is unable to move the tractor to a dealer&#39;s site, the company will arrange to repair the unit at the consumer&#39;s home.
<h2>DE&#39;s Topline Dips Y/Y in Q3</h2>
Deere reported third-quarter fiscal 2024 earnings of $6.29 per share, which beat the Zacks Consensus Estimate of $5.80. The bottom line, however, plunged 38% from the prior-year quarter.
This was due to lower shipment volumes across all segments, reflecting weak demand, which was somewhat negated by the company&#39;s pricing strategies and cost-saving measures.
Net sales of equipment operations (comprising Agriculture, and Turf, Construction and Forestry) were $11.39 billion, down 19.9% year over year. However, net sales topped the Zacks Consensus Estimate of $10.87 billion. Total net sales (including financial services and others) were $13.15 billion, down 16.8% year over year.
<h2>Deere&#39;s 2024 Net Income Outlook Indicates Y/Y Dip</h2>
Deere stated that in the wake of challenging conditions in the global agricultural and construction sectors, the company will align its production with demand levels and also take steps to reduce costs. Deere maintained its guidance of net income for fiscal 2024 at $7 billion. The view suggests a 31% decline from net income of $10.2 billion reported in fiscal 2023.
Net sales for Production &amp; Precision Agriculture are expected to decrease 20-25% year over year in fiscal 2024. Sales of Small Agriculture &amp; Turf are expected to dip 20-25%. Deere projects sales of Construction &amp; Forestry to be down 10-15%. The Financial Services segment&#39;s net income is expected to be $720 million.
<h2>DE Share Price Outperforms Industry</h2>
DE shares have gained 8.7% in the past year compared with the industry&#39;s growth of 4%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/1c/79542.jpg?v=1652687335" />
Image Source: Zacks Investment Research
<h2>Deere&#39;s Zacks Rank &amp; Stocks to Consider</h2>
DE currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the Industrial Products sector are Crane Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cr#NYSE">CR</a>), Flowserve Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fls#NYSE">FLS</a>) and RBC Bearings Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rbc#NYSE">RBC</a>). Each stock presently carries a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for Crane&#39;s 2024 earnings is pegged at $5.07 per share. The consensus estimate for 2024 earnings has moved north by 6% in the past 60 days. The company has a trailing four-quarter average earnings surprise of 11.2%. CR shares have gained 75.2% in a year.
Flowserve has an average trailing four-quarter earnings surprise of 18.2%. The Zacks Consensus Estimate for FLS&#39; 2024 earnings is pinned at $2.76 per share, which indicates year-over-year growth of 31.6%. The consensus estimate for 2024 earnings has moved north by 4% in the past 60 days. The company&#39;s shares have gained 27.5% in a year.
The Zacks Consensus Estimate for RBC Bearings&#39; fiscal 2025 earnings is pegged at $9.71 per share. The consensus estimate for 2025 earnings has moved north by 1.4% in the past 60 days. The company has a trailing four-quarter average earnings surprise of 4.7%. RBC shares have gained 27.2% in a year.
<a href="https://www.zacks.com/stock/news/2342803/deere-recalls-its-compact-utility-tractors-for-brake-failure-risk?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2342803">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Guidance

Deere Recalls Its Compact Utility Tractors for Brake Failure Risk

Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has received notice from the listing qualifications department staff of The Nasdaq Stock Market ("Nasdaq") stating that the Company has not regained compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company's common stock has remained below $1.00 per share through the initial 180-day compliance period ended September 23, 2024. The Company is not eligible for a second 180-day period because it does not comply with the minimum stockholders' equity requirement for initial listing on The Nasdaq Capital Market. The Nasdaq Hearings Panel will consider this matter in rendering a determination regarding the Company's continued listing on The Nasdaq Capital Market at an upcoming hearing which will also consider the Company's non-compliance with the $2.5 million stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1).

ENSC

Ensysce Biosciences Receives Notice from Nasdaq; The Company Is Not Eligible For A Second 180-Day Period Because It Does Not Comply With The Minimum Stockholders' Equity Requirement For Initial Listing On The Nasdaq Capital Market

General

Global Mofy AI Limited Announces Receipt Of Notification From Nasdaq Due To Closing Bid Price Requirement

AECOM (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/acm#NYSE">ACM</a>) won a contract from the Los Angeles County Metropolitan Transportation Authority (Metro) to provide program management, design and engineering services.
Banking on its Sustainable Legacies strategy, ACM will support Metro&#39;s ambitious goal of transitioning its bus fleet to Zero Emission Buses. Also, it will focus on charging infrastructure conceptual design, specification, and procurement. Its expertise will help guide the seamless transition to zero-emission operations, offering innovative solutions to complex transportation challenges.
The sustainable and efficient transit system aims to reduce greenhouse gas emissions while improving air quality for Los Angeles County residents. On an impressive note, the initiative is one of the largest electric bus programs in the United States and is supported by the Infrastructure Investment and Jobs Act.
<h2>ACM&#39;s Stock Performance</h2>
The company&#39;s shares have gained 11.6% so far this year, which is nearly one-third of the Zacks Engineering - R and D Services industry&#39;s 36.2% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/db/79473.jpg?v=371988059" />
Image Source: Zacks Investment Research
This Zacks Rank #4 (Sell) company has been ailing from labor shortages, particularly in skilled trades. Inflationary pressures, particularly in raw materials and energy, could also be bothering margins. This apart, broader economic uncertainties, such as fears of a recession or global economic slowdown, might be impacting the infrastructure sector. Investors could be cautious about long-term infrastructure spending, especially if government funding slows down.
<h2>ACM&#39;s Strong Backlog &amp; Global Demand Drive Raises Hope</h2>
Mitigating the above-mentioned headwinds, AECOM has been experiencing robust growth across all its segments, backed by strong pipeline visibility for the upcoming quarters. Healthy state and local budgets, along with increased private sector investments in water and energy transitions, have contributed to this upward trend.
Additionally, the U.K. water market is expected to see accelerated growth over the next five years, driven by a near doubling of AMP8 funding. AECOM&#39;s deep expertise with major water utilities positions it well to benefit from this expansion.
Global demand for infrastructure development is rising, further increasing the need for AECOM&#39;s services. As of the fiscal third-quarter end, the total backlog was $23.36 billion compared with $23.21 billion reported in the prior-year period. The current backlog level includes 54.8% contracted backlog growth.
Ongoing contract wins are expected to boost prospects. Global infrastructure spending trends remain strong, providing further opportunities for AECOM&#39;s continued expansion.
<h2>Key Picks</h2>
Some better-ranked stocks in the same space are:
Sterling Infrastructure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/strl#NASDAQ">STRL</a>) presently sports a Zacks Rank #1 (Strong Buy). Sterling Infrastructure has a trailing four-quarter earnings surprise of 17.4%, on average.
The Zacks Consensus Estimate for STRL&#39;s 2024 sales and earnings per share indicates a rise of 9.7% and 26.6%, respectively, from the prior-year levels.
Howmet Aerospace Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hwm#NYSE">HWM</a>) presently carries a Zacks Rank #2 (Buy). HWM has a trailing four-quarter earnings surprise of 10.9%, on average.
The Zacks Consensus Estimate for HWM&#39;s 2024 sales and EPS indicates a rise of 12.6% and 40.8%, respectively, from the prior-year levels.
M-tron Industries, Inc. (AMEX:MPTI) currently carries a Zacks Rank #2. It has topped earnings estimates in three of the trailing four quarters and missed once, with an average surprise of 9.2%.
The Zacks Consensus Estimate for MPTI&#39;s 2024 sales and EPS indicates a rise of 16.1% and 76.6%, respectively, from prior-year levels.
<a href="https://www.zacks.com/stock/news/2342821/aecom-wins-contract-to-support-la-metro-s-zeb-transition?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2342821">To read this article on Zacks.com click here.</a>

Mid Cap

Contracts

Small Cap

MPTI

STRL

AECOM Wins Contract to Support LA Metro's ZEB Transition

Universal Ibogaine

Discussion surrounding science, industry and psychedelics reform is experiencing an all-time high, and 2024 promises to not only continue but further this trend. 



In 2023, the psychedelics market saw transformative expansion driven by favorable trial outcomes, attracting significant investments that reshaped the industry. Driven by scientific advances and changing perceptions, some recent predictions predict the global market will be worth $7.1 billion by 2032, bringing along increased investor interest.



And yet, as much as the psychedelics industry has huge potential, it is also constrained by ambiguity. The positive path in psychedelics research has not been directly reflected in investments in publicly traded companies in the sphere.



A <a href="https://www.benzinga.com/markets/cannabis/24/02/37070368/groundbreaking-fda-reviews-mdma-therapy-for-ptsd-accepts-new-drug-application">key decision by the FDA</a> concerning MDMA therapy this summer was seen by many as a potential watershed moment either cementing this healthcare sector's legitimacy or reinforcing its uncertain nature.



In this state of affairs, Benzinga is providing a concise recollection of the most significant events in the field through insightful exclusive comments from experts in various specialized areas within the ecosystem.



<h3 class="wp-block-heading">A Look From The UK: The Beckley Ecosystem</h3>



A specialist in psychedelic startup incubation, <a href="https://www.benzinga.com/markets/cannabis/23/10/35452135/ketamine-company-acquisition-alert-beckley-waves-adds-nue-life-to-its-portfolio">Beckley Waves</a> co-founder Rock Feilding-Mellen poses that the most important trend in 2024 will be "a concerted effort and focus" on building infrastructure for psychedelic-assisted therapies (PAT) ahead of the anticipated FDA approval of Lykos Therapeutics' (formerly MAPS PBC) MDMA-assisted therapy by year&#8217;s end.&nbsp;



His view was previewed in a recently announced partnership between Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) and Greenbrook TMS to scale commercial delivery models: "One thing most people still haven&#8217;t recognized is that PAT is a unique treatment that requires not only the psychedelic substance but psychotherapy and specific clinical infrastructure needs that are still rare."



Regarding the evolving legal landscape, Feilding-Mellen views it as "still very much a ‘Wild West'." In this sense, he advises companies seeking to enter this quasi-legal gray area to be cautious about how they position their offerings and the claims they make.&nbsp;



"For example, while several countries allow psychedelic retreats, such as Jamaica, operators can get into trouble by making medical claims about the efficacy of psychedelics in the treatment of PTSD or other mental health issues. This phenomenon has featured prominently in the cannabis market and perhaps even more so in the emerging psychedelic space," Feilding-Mellen said.



The FDA's potential approval of MDMA therapy allowing physicians to prescribe the treatment, Feilding-Mallen says at the state level all eyes will be on Colorado's rollout of its commercial legalization framework. 



"What appears to be opening and a major milestone, is an increase in federal research funding for psychedelic clinical trials. The market opportunities will be those that support clinical trial development, onboarding providers to the PAT paradigm, and enabling safe, legal, and accessible care,' he said.



Neil Markey, co-founder of Jamaica and Netherlands-based <a href="https://www.benzinga.com/markets/cannabis/23/11/35974773/exclusive-beckley-retreats-kicks-off-2024-with-new-program-for-personal-discovery-transformation">Beckley Retreats</a>, sees psychedelics' use will likely evolve into "the betterment of the well.&#8221;&nbsp;



"Use cases will expand beyond clinical application to support mental well-being, creativity, team building. At Beckley Retreats, we have begun to see corporate leaders utilizing psychedelic treatment as a means to personal growth, leading to more adaptable, empathetic business leaders who can foster better communication, teamwork and decision-making. The impacts can improve employee engagement, job satisfaction, and company performance and growth," Markey says.&nbsp;



A key challenge the space will face this year: "Wounded healers or practitioners who are drawn to psychedelic treatment but have not done enough of their own personal work and healing," Markey said. Also, alternative energy medicines including reiki and grounding are expected to grow in popularity in 2024.&nbsp;



John Yoo, CEO of <a href="https://www.benzinga.com/markets/cannabis/24/02/37394447/beckley-academys-open-source-psychedelic-therapy-learning-framework-is-out-whats-it-all-about-au">Beckley Academy</a>, spoke on the clinician training that will be necessary for psychedelic therapies to scale.&nbsp;



"We are in a state of transition, so everything that happens related to psychedelic use (medical or not) will draw attention and scrutiny. Safety and efficacy will continue to be studied and analyzed as treatments, like MDMA-assisted therapy, move from a clinical trial model to health care. Standards around dosing and practice will be introduced for ketamine-assisted therapy. Telehealth KAT practices may come under additional regulation or scrutiny as more people seek accessible treatment."



Yoo says the team also expects to see an increased emphasis on harm reduction education versus a &#8220;just say no&#8221; approach toward promoting a better understanding and safer access to psychedelics.



"From the lens of educators, we see a tension between offering high-quality education -which gives practitioners enough time, depth, skills practice and supervision- and making training affordable and efficient so that the field can meet the demand for PAT," Yoo added. "Less-experienced therapists coming to this work earlier in their careers will need ample experiential training, mentorship and supervision to safely and ethically sit with clients."&nbsp;



He foresees a shift towards MDMA-assisted therapy training, although it's still unclear which organizations will be able to certify therapists.



<h3 class="wp-block-heading">Ketamine Specialty Meets MDMA</h3>



Charles Patti is CEO of Florida-based ketamine clinic MY Self Wellness, co-founder of nonprofit Warriors of Consciousness and an advocate for mental health and psychedelic medicine as his personal healing story for overcoming addiction involves the use of psilocybin mushrooms, DMT and ketamine.



Expected FDA approval for MDMA therapy will likely impact all areas of psychedelic medicine, including existing ketamine clinics. As such, MY Self Wellness is getting ready to provide joint ketamine and MDMA therapy as a treatment offering for PTSD.



"It will be a great addition to our ketamine services. Ketamine and MDMA are like peanut butter and jelly. MDMA is a ‘heart opener' and may be very beneficial for talk therapy. It can be used to talk through one's traumatic experiences, while ketamine is more of a deeper dive psychedelic experience," says Patti.&nbsp;



The clinic recently partnered with several veteran community organizations to offer psychedelic treatment (for the moment solely ketamine) to this population. 



In Patti's words, "Veterans or those with PTSD can get to the root cause of what's making them suffer by using these two healing therapies therapeutically," to be provided in separate days.



He sees the veteran community is helping break the negative stigma tied to psychedelic therapy to treat mental health conditions.&nbsp;



"People listen to veterans because they have served our country and don't want them to suffer. Before, the government would have never approved psychedelics' use for mental health purposes. However, due to what it's doing with our veteran and first responder community, there has been more of a positive narrative."&nbsp;



Further, he sees celebrities going public with their psychedelic use stories, as well as increasing data being collected with clinical studies conducted by major institutions like MAPS, Johns Hopkins and Imperial College London, the taboo reputation is turning more positive and doubts on the efficacy of the medicine are going away.&nbsp;



"The expected impact of the direction of psychedelic treatment will be similar to those who tried to penetrate the ketamine industry. Many individuals will fail to come into the market, because they are trying to make a quick return on their investment. Those who are passionate about psychedelics and helping others will play the long game by waiting for the laws to pass and eventually be successful in their endeavors. With the intention to prevent inexperienced companies from just opening up shop once the FDA approves MDMA, it has been speculated that the law may require clinics to have been open for over a couple of years in order to integrate MDMA therapy," says Patti.



Even though the underground market will "always exist" as "illegal use is tantalizing because people want what they can't have", Patti says he&#8217;s certain that the normalization of psychedelics will shift the entire mental health paradigm. 



"People are going to visually see something that really works and are not going to be able to say it's illegal anymore. It will shift these long-term psychedelic healing modalities to become more mainstream. As a result, people will stop relying on pills and multiple medications every day. 20 years from now, Xanax and antidepressants may become a thing of the past and psychedelic medicine will be the new standard."



<h3 class="wp-block-heading">Expert Investor's Take</h3>



Known by some as "the psychedelic concierge to the stars,&#8221; Zappy Zapolin is a prominent figure in the field and a longtime trendspotter in many industries. <a href="https://www.benzinga.com/general/biotech/24/02/37397999/podcast-post-frenzy-psychedelics-investing-and-reclaiming-the-right-to-pursue-happiness-with-zapp">Among his many hats</a>, he currently advises companies in the psychedelic sector including Psycheceutical Bioscience (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BWVI#OTC">BWVI</a>) (currently conducting clinical trials in Australia for a topical ketamine delivery for PTSD treatment) and Canada-based Universal Ibogaine (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IBOGF#OTC">IBOGF</a>).



Reflecting on three decades of market experiences, Zapolin sees parallels between historical market bubbles, such as the Wall Street crash and the rise of the internet bubble, all sharing a recurring pattern: quality emergence post-bubble burst. 



In this sense, he sees the psychedelics industry is at a great moment "where the hype is gone, but the really good science and some very recent indicators of companies getting large funding in this space remain.&#8221;



During the internet bubble, Zapolin seized opportunities by purchasing domain names at low prices. He views a similar trend in the psychedelics market, although he does emphasize on the need to identify quality companies, with enough (and influential) funding and expertise to perform successful R&amp;D and provide long-term gains. &#8220;You start in the beginning of a trillion-dollar industry, and one or two of your several quality investments work out.&#8221;



His investments in the sector follow mentor Mike Milken's advice on the importance of intellectual property for value creation. And then, "wealth is the byproduct.&#8221; 



As much as he is a firm believer in psychedelics as healing modalities, Zapolin is particularly pumped about ibogaine's therapeutic benefits for addiction treatment, and has joined Lamar Odom to create awareness on the substance's vast potential. "Ibogaine's work is like a full reset -mental, physical, wiping your prefrontal cortex so you don&#8217;t have cravings."



Photo by <a href="https://unsplash.com/@cristian1?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Cristian Escobar</a> on <a href="https://unsplash.com/photos/person-holding-lighted-sparklers-abkEAOjnY0s?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Unsplash</a>.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Universal Ibogaine

News

Latest news for Universal Ibogaine (OTC:IBOGF) Stock

Wednesday, March 06, 2024